Xcout Intel
Centaurus Therapeutics, Inc.
Centaurus Therapeutics is a clinical-stage biotechnology company that develops first-in-class small-molecule therapies targeting ceramides to treat cardio-kidney-metabolic (CKM) diseases. The company's lead oral asset, CNT2130, inhibits DES1 to reduce excess ceramide production and restore lipid balance for patients suffering from organ decline.
Subscribe to see Centaurus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Centaurus Therapeutics, Inc. at a glance
Centaurus Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $4M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $2M in June 2026. Xcout tracks 1 named person at Centaurus Therapeutics, Inc., including Dr Mike Westby (Chief Scientific Officer).
Centaurus Therapeutics, Inc. leadership
- Dr Mike WestbyChief Scientific Officer
Centaurus Therapeutics, Inc. funding rounds
At least $4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $2M | 7 named | |
| SEC Form D filing | $2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Centaurus Therapeutics, Inc. competitors
A few of Centaurus Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Grand Rapids, Michigan, focused on developing innovative therapies for metabolic and liver diseases.
Centessa Pharmaceuticals LLC is a biotechnology research company headquartered in Boston, Massachusetts, United States. The company comprises leaders, innovators, and scientists dedicated to pursuing and developing transformational medicines for patients.
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Akero Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is dedicated to developing transformational therapies for metabolic dysfunction-associated steatohepatitis and other metabolic diseases.
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.
Get Centaurus Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Centaurus Therapeutics, Inc. in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access